An interventional study of Multiparametric Prostate MRI in Prostate Cancer and Prostate Cancer Stage, sponsored by Gulhane Training and Research Hospital. Status unknown at 1 site in Turkey. Open to male participants. Per ClinicalTrials.gov, last updated 2022-06-28.
Sponsored by Gulhane Training and Research Hospital · Not applicable, Interventional, and Diagnostic
In this study, it is aimed to compare the lesion location, lesion size, local and distant metastases detection rates of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer.
The pathologies of the patients who were decided to undergo radical prostatectomy as a treatment will also be compared with the staging tests.
6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.
This study's planned enrollment of 47 is below the median of 58 across 4,822 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Gulhane Training and Research Hospital is the lead sponsor of 44 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Comparison of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer
Also known as: Ga-68 PSMA PET
Lesion location
Both MRI and PET results will be compared. Lesion location will be defined as "left", "right", "apical", "basal", "midline".
Time frame: Between prostate biopsy and curative treatment decision , usually 2 month
Lesion Size
Both MRI and PET results will be compared, Lesion size will be stated in milimeters.
Time frame: Between prostate biopsy and curative treatment decision , usually 2 month
Lymph node involvement
Both MRI and PET results will be compared. Involvement will be stated as "exist", "non-exist".
Time frame: Between prostate biopsy and curative treatment decision , usually 2 month
Extraprostatic involvement
Both MRI and PET results will be compared. Involvement will be stated as "exist" , "non-exist".
Time frame: Between prostate biopsy and curative treatment decision , usually 2 month
Local and distant metastasis
Both MRI and PET results will be compared. Metastasis will be stated as "exist" , "non-exist".
Time frame: Between prostate biopsy and curative treatment decision , usually 2 month
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gulhane Training and Research Hospital